NPCE (NeuroPace) Accounts Payable: $4.51 Mil (As of Mar. 2026)


NPCE NeuroPace Inc NPCE
68 GF Score
Price $16.23
GF Value $11.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is NeuroPace Accounts Payable?

NeuroPace NPCE +2.08% 68 Accounts Payable is $4.51 Mil as of Mar. 2026. GuruFocus rates NPCE with a GF Score™ of 68/100 and a GF Value™ of $11.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

NeuroPace's Accounts Payable for the quarter that ended in Mar. 2026 was $4.51 Mil.

NeuroPace's quarterly Accounts Payable declined from Sep. 2025 ($4.59 Mil) to Dec. 2025 ($2.22 Mil) but then increased from Dec. 2025 ($2.22 Mil) to Mar. 2026 ($4.51 Mil).

NeuroPace's annual Accounts Payable increased from Dec. 2023 ($2.33 Mil) to Dec. 2024 ($2.95 Mil) but then declined from Dec. 2024 ($2.95 Mil) to Dec. 2025 ($2.22 Mil).

NeuroPace Accounts Payable Historical Data

* Premium members only.

The historical data trend for NeuroPace's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroPace Accounts Payable Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 1.38 2.15 2.33 2.95 2.22

NeuroPace Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 4.72 4.59 2.22 4.51
NPCE
68GF Score
NeuroPace Inc NPCE
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroPace Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $4.51 Mil mean?
NeuroPace (NPCE) has a Accounts Payable of $4.51 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on NeuroPace and its competitors.
Is NeuroPace's Accounts Payable too high?
NeuroPace's current Accounts Payable is $4.51 Mil. Overall, NeuroPace has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's Accounts Payable compare to CLPT and CTKB?
NeuroPace's Accounts Payable of $4.51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on NeuroPace and its competitors. NeuroPace's current Accounts Payable is $4.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $16.23 — trading 42.2% above its estimated fair value. The current Accounts Payable is $4.51 Mil. NeuroPace's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For NeuroPace (NPCE), the current Accounts Payable is $4.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroPace (NPCE) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued. The current stock price of $16.23 is trading 42.2% above its estimated GF Value™ of $11.41. GuruFocus considers NeuroPace to be Significantly Overvalued.

Key valuation signals for NPCE:

  • Accounts Payable: $4.51 Mil
  • GF Value™: $11.41 vs. price of $16.23 (42.2% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroPace Business Description

Address 455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
68GF Score

Get the complete analysis for NPCE

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.23
Price
$11.41
GF Value